Cytotoxic chemotherapy also remains an option for patients with well-differentiated UPO-NETs and may be the preferred treatment strategy in patients with high disease burden, higher Ki-67, poor 68GaPET, and/or significant FDG-PET uptake, or in patients for whom rapid tumor shrinkage is a desirable goal. Here, MKI67 is linked to neoplasm.